Pure Biologics Valuation Multiples

Pure Biologics Overview

About Pure Biologics

Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

Founded

2010

HQ

Employees

60

Website

purebiologics.pl

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: —

EBITDA: ($3M)

EV

$14M

Valuation Multiples

Multiples.vc

Start free trial

Pure Biologics Financials

Pure Biologics reported last fiscal year revenue of — and negative EBITDA of ($3M).

In the same fiscal year, Pure Biologics generated ($13K) in gross profit, ($3M) in EBITDA losses, and had net loss of ($5M).

Pure Biologics P&L

In the most recent fiscal year, Pure Biologics reported revenue of — and EBITDA of ($3M).

Pure Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Pure Biologics Stock Performance

Pure Biologics has current market cap of $10M, and enterprise value of $14M.

Pure Biologics' stock price is $0.80.

Pure Biologics Valuation Multiples

Pure Biologics trades at (4.3x) EV/EBITDA.

Pure Biologics Financial Valuation Multiples

As of April 19, 2026, Pure Biologics has market cap of $10M and EV of $14M.

Equity research analysts estimate Pure Biologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pure Biologics has a P/E ratio of (1.8x).

Pure Biologics Margins & Growth Rates

Pure Biologics' revenue in the last fiscal year declined by (100%).

Pure Biologics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.

Pure Biologics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Pure Biologics M&A Activity

Pure Biologics acquired XXX companies to date.

Last acquisition by Pure Biologics was on XXXXXXXX, XXXXX. Pure Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Pure Biologics Investment Activity

Pure Biologics invested in XXX companies to date.

Pure Biologics made its latest investment on XXXXXXXX, XXXXX. Pure Biologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).